7.Low-level viremia in nucleoside analog-treated chronic hepatitis B patients.
Qian ZHANG ; Da-Chuan CAI ; Peng HU ; Hong REN
Chinese Medical Journal 2021;134(23):2810-2817
Low-level viremia (LLV) was defined as persistent or intermittent episodes of detectable hepatitis B virus (HBV) DNA (<2000 IU/mL, detection limit of 10 IU/mL) after 48 weeks of antiviral treatment. Effective antiviral therapies for chronic hepatitis B (CHB) patients, such as entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF), have been shown to inhibit the replication of HBV DNA and prevent liver-related complications. However, even with long-term antiviral therapy, there are still a number of patients with persistent or intermittent LLV. At present, the research on LLV to address whether adversely affect the clinical outcome is limited, and the follow-up treatment for these patients is open to question. At the same time, the mechanism of LLV is not clear. In this review, we summarize the incidence of LLV, the association between LLV and long-term outcomes, possible mechanisms, and management strategies in these patient populations.
Antiviral Agents/therapeutic use*
;
DNA, Viral
;
Hepatitis B virus/genetics*
;
Hepatitis B, Chronic/drug therapy*
;
Humans
;
Nucleosides/therapeutic use*
;
Tenofovir/therapeutic use*
;
Treatment Outcome
;
Viremia/drug therapy*
8.To evaluate treatments of chronic hepatitis B.
Chinese Journal of Hepatology 2006;14(6):402-405
9.Effect of different therapeutic regimens on serum interleukin-21 levels in patients with chronic hepatitis B.
Min ZOU ; Minmin LI ; Xiaojuan LI ; Yuanping ZHOU ; Shuwen LIU
Journal of Southern Medical University 2012;32(9):1284-1286
OBJECTIVETo detect serum interleukin-21 (IL-21) levels in patients with chronic hepatitis B receiving different therapeutic regimens.
METHODSA total of 198 patients with inactive chronic hepatitis B were divided into 3 groups according to the therapeutic regimens, namely interferon (IFN)-treated group (IFN group, n∓38), nucleoside analogue-treated group (NA group, n∓72) and untreated group (control group, n∓88). IL-21 and serum hepatitis B virus (HBV) markers were detected in these patients using enzyme-linked immunosorbent assay (ELISA), and the liver function indices were measured with an auto-biochemical analyzer.
RESULTSThe serum IL-21 levels in Con and IFN groups were significantly higher than those in NA group (102.29∓14.03, 123.01∓38.26, and 48.10∓7.06 pg/ml, respectively, P<0.05). When all the patients were regrouped according to the status of HBeAg, serum IL-21 level was 114.83∓19.88 pg/ml in HBeAg-negative group (n∓105), significantly higher than that of 61.53∓6.61 pg/ml in HBeAg-positive group (n∓93) (P<0.05). Bivariate correlation analysis showed no significant correlations between IL-21 and liver function indices.
CONCLUSIONThe immunomodulator IFN might be capable of increasing serum IL-21 levels, while nucleoside analogues can decrease IL-21 level in patients with chronic hepatitis B. HBeAg-negative patients have a significantly higher serum IL-21 level, suggesting that the expression of HBeAg might result in IL-21 depression.
Adult ; Female ; Hepatitis B e Antigens ; blood ; Hepatitis B, Chronic ; blood ; drug therapy ; Humans ; Interferons ; therapeutic use ; Interleukins ; blood ; Male ; Nucleosides ; therapeutic use
10.Promotion of HBeAg seroconversion/loss in patients with chronic hepatitis B following the switch from nucleoside drugs to telbivudine and adefovir.
Sunan CUI ; Mingming WANG ; Yanxue GONG
Chinese Journal of Hepatology 2014;22(10):776-778
Adenine
;
analogs & derivatives
;
therapeutic use
;
Drug Combinations
;
Hepatitis B e Antigens
;
blood
;
Hepatitis B, Chronic
;
drug therapy
;
Humans
;
Nucleic Acid Synthesis Inhibitors
;
therapeutic use
;
Nucleosides
;
antagonists & inhibitors
;
biosynthesis
;
Organophosphonates
;
therapeutic use
;
Thymidine
;
analogs & derivatives
;
therapeutic use
Result Analysis
Print
Save
E-mail